1. BIOSAFETY. BIORISK ASSESSMENT
Dr. Gabriel Ionescu
Cantacuzino Institute,
“Carol Davila” U.M.Ph. Bucharest

3. Biohazard definition translated into Romanian PERICOL BIOLOGIC NU
(adapted from ISO/IEC Guide 51:1999)
Potential source of harm caused by biological agents or toxins
translated into Romanian
PERICOL BIOLOGIC NU
RISC BIOLOGIC

4. Biorisk definition (adapted from ISO/IEC Guide 51:1999)
combination of the probability of occurrence of harm and the severity of that harm where the source of harm is a biological agent or toxin
NOTE The source of harm may be an unintentional exposure, accidental release or loss, theft, misuse, diversion, unauthorized access or intentional unauthorized release

5. Specific guidelines
Available on See Section “Biosiguranta – Biosecuritate”

6. Directives, guidelines, standards
EU DIRECTIVES
EU Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work - HG 1092/2006
EC Directive on the Contained Use of Genetically Modified Organisms – OU 77 and 78 / 2007
GUIDELINES
Laboratory Safety Manual - WHO
Biosafety in Microbiological and Biomedical Laboratories (BMBL) - CDC
The Laboratory Biosafety Guidelines - Health Canada
Guidelines for Research Involving Recombinant DNA Molecules EC - NIH
Biorisk management. Laboratory biosecurity guidance - WHO
Biosafety risk assessment methodologies – Sandia Report
STANDARDS
OHSAS 18001
ISO 15190: Medical laboratories - Requirements for safety
CWA 15793: Laboratory biorisk management standard

7. See WHO Biosafety manual
Biosafety definition
All measures that prevent accidentally exposure at biological agents (micro-organisms and toxins) and infections and their released in environment
See WHO Biosafety manual
biological agent (adapted from EU Directive 2000/54/EC)
any microorganism including those which have been genetically modified, cell cultures and endoparasites, which may be able to provoke any infection, allergy or toxicity in humans, animals or plants

8. 2011 – The Year of Biosafety
EBSA announced 2011 “Year of Biosafety in Europe” as an initiative to support the newly established International Federation of Biosafety Associations (IFBA)
The European Centre for Disease Prevention and Control (ECDC) together with the European Biosafety Association (EBSA), a special session at 14th EBSA Annual Conference (April 13-15th, Portugal) to bring together laboratory and biosafety experts to discuss the development of effective pan-European biosafety networks

9. 2011, the year of building international biosafety communities
Declaration of International Federation of Biosafety Association on Advancing Global Biosafety and Biosecurity
2011, the year of building international biosafety communities
Longer-term goals
Promoting biosafety education, particularly of the younger generation, involving curriculum development within a common framework and a common methodology for evaluation.
Supporting appropriate and practical legislative framework development.
Developing a strategy to obtain funding for applied biosafety research programs

10. Declaration of International Federation of Biosafety Association on Advancing Global Biosafety and Biosecurity
Short term goals
Raising awareness from the political and public perspectives, and encouraging collaboration among the human and animal health communities
Developing sustainable biosafety associations and mapping gaps and needs
Providing advice to the competent national authorities and services for the improvement of efficient waste management (through disseminating knowledge of appropriate systems, tools and technologies for public and veterinary health environments).
Promoting human and laboratory capacity building with proper identification of gaps and needs (using the best available concepts, principles and practices)

11. special modules in biosafety practices
ECDC
EPIET and EUPHEM training programmes
special modules in biosafety practices
exchange of biological materials
testing methods
training of laboratory staff
ECDC BioRisk Initiative for Capacity building and Knowledge base development (BRICK project)

12. Biorisk assessment definition
(adapted from OHSAS 18001:2007)
Process of evaluating the biorisk(s) arising from a biohazard(s), taking into account the adequacy of any existing controls, and deciding whether or not the biorisk(s) is acceptable
As defined by Kaplan and Garrick, risk analysis consists of answering three specific questions:
what can happen?
what is the chance that it will happen?
if it happens, what are the consequences?.

13. Risk assessment strategy

14. Characteristics risk assessment is proactive rather than reactive
risk assessment is CAREFUL judgment
risk assessment is proactive rather than reactive
assessments can be qualitative, semi-quantitative or quantitative
risk assessment methodology should be:
identified
implemented
maintained
risk assessment is first step to control (reduce or eliminate) the hazards
risk assessment will provide a guide for the selection of appropriate
- biosafety levels needs
- microbiological practices
- safety equipment
- facility safeguards

15. Assess the capability of the laboratory staff to control hazards
- training
- technical proficiency
- good habits of all members of the laboratory
- operational integrity of containment equipment
- facility safeguards

16. New risk assessment or review of an existing one when:
the introduction of new biological agents
new work or changes to the programme of work
alterations to work flow or volume
new construction / modifications to laboratories, equipment or its operation
introduction of altered and unplanned staffing arrangements

17. New risk assessment or review of an existing one when:
significant alterations to Standard Operating Procedures (SOPs) or working practices (e.g. disinfection/waste management methodologies, PPE provision / usage entry/exit protocols, etc.);
unexpected events that may have relevance for the management of biorisks are observed

18. New risk assessment or review of an existing one when:
actual or potential non-conformity with internal / external rules and regulations is identified
as part of the existing management system review process (e.g. annually or at another appropriate and predetermined frequency)

19. Biorisk definition
Biosafety risks are defined as a function of the likelihood of infection by the agent and the likelihood of exposure through an infectious route based on the procedures and work practices and the consequences of disease assuming infection

20. Biosafety risks is a function of:
likelihood of
infection by the agent
exposure through an infectious route
consequences

21. 4 scenarios Risk to individuals in the laboratory
Risk to an individual outside the laboratory (the human community)
Risk to animals outside the laboratory (the animal community)
Risks to humans and animals resulting from a secondary exposure

22. Routes of exposure
droplets or droplet nuclei (upper or lower respiratory tract)
compromised skin or direct injection into the blood stream
the mucosal membranes
the gastrointestinal tract

23. Consequences of disease in humans assuming infection (1)
Does this agent or one of its by-products cause a carcinogenic or mutagenic reaction in a human host?
Does this agent have toxin or enzyme production which has a negative impact in a healthy human host?
Does this agent suppress a human host’s immune system? (E.g. cause dramatic suppression which renders the host susceptible other infections)
Does this agent have the ability to mutate once in a host or in the natural environment to become infectious through new route or new hosts, or to cause increased consequences?
What is the duration of illness (the average length of time of clinical signs of infection) in a normally healthy human host?
What is the severity of illness (the average severity of illness, ranging from no signs of illness to hospitalize in critical condition) in a normal health human host?
What is the duration of infection (the length of time the host is infected with the organism) in a normal healthy human host?

24. Consequences of disease in humans assuming infection (2)
Does this disease cause any long-term conditions (sequelae) in a normal healthy human host?
What is the frequency of death in humans caused by this disease in a defined population during a specified interval of time (Mortality Rate)?
What level of national / international reporting is required for outbreaks of this disease?
Do effective diagnostic tests exist for humans?
Do post exposure treatments (including immuno-globulin, vaccines and antimicrobials) exist for humans?
Do preventative measures (vaccines) exist for humans?

25. Consequences of disease in animals assuming infection
If the agent infects animals, what is the expected morbidity rate to a naive but otherwise healthy animal population?
What level of national or international reporting is required for outbreaks of this disease?
What species of animals can this agent infect?
Do effective diagnostic tests exist for animals?
Do post exposure treatments (including immuno-globulin, vaccines and antimicrobials) exist for animals?
o Do preventative measures (vaccines) exist for animals?

26. The risk assessment should categorize risks
the use of a risk matrix identifying likelihood and consequence categories
e.g. high, moderate and low zones
the acceptability of risk levels should be defined
the inherent risk from the biological agents and toxins
e.g. from risk grouping descriptions, material safety data sheets etc.

27. biosafety levels ≠ risk group
Risk assessment
CAREFUL judgment
biosafety levels ≠ risk group
Ideally, a risk assessment should be conducted in a manner which is standardized and systematic allowing it to be repeatable and comparable.
A risk assessment will determine the degree of correlation between an agent’s risk group classification and biosafety level

28. Classification of infective microorganisms by risk groups
Risk Group 1 (no or very low individual and community risk)
A microorganism that is unlikely to cause human or animal disease .
Risk Group 2 (moderate individual risk, low community risk)
A pathogen that can cause human or animal disease but is unlikely to be a serious hazard to laboratory workers, the community, livestock or the environment. Laboratory exposures may cause serious infection,
Effective treatment and preventive measures are available and the risk of spread of infection is limited.
Risk Group 3 (high individual risk, low community risk)
A pathogen that usually causes serious human or animal disease but does not ordinarily spread from one infected individual to another.
Effective treatment and preventive measures are available.
Risk Group 4 (high individual and community risk)
A pathogen that usually causes serious human or animal disease and that can be readily transmitted from one individual to another, directly or indirectly.
Effective treatment and preventive measures are not usually available.

29. Relation of risk groups to biosafety levels, practices and equipment
Laboratory type
Laboratory practices
Safety equipment 1
Basic – Biosafety Level 1
Basic teaching,
research
GMT
None; open bench work 2
Basic – Biosafety Level 2
Primary health
services;diagn.
GMT plus protective
clothing, biohazard
sign
Open bench plus BSC for potential aerosols 3
Containment Biosafety Level 3
Special
diagnostic,
As Level 2 plus special clothing, controlled access, directional air flow
BSC and/or other primary devices for
all activities 4
Maximum
Biosafety Level 4
Dangerous pathogens unit
As level 3 plus airlock entry, shower exit, special waste disposal
Class III BSC
Positive presure suit + BSC II
Double door autoclave
Filtered air

30. Biorisk Assessment Sheet

31. Material Safety Data Sheet (MSDS)

32. FALSE sense of security
FINAL REMARKS
Train and RETRAIN and RETRAIN and .. until good microbiological techniques and safety precautions become second nature
Inadequate training on :
- PPE use
- correct use and maintenance of equipment
FALSE sense of security